Nuvo’s Topical Antifungal (NRI-1002) is an antifungal medication intended for use in treating onychomycosis (a nail fungal infection), is the second product based on the Corporation’s Transdermal Drug Delivery research. Ex vivo permeation studies have shown that a combined transdermal carrier-antifungal medication can penetrate cadaver nails and deliver the active drug through the disease site and into the nail bed.
Onychomycosis is responsible for approximately half of all nail disease and affects an estimated 15% to 20% of people over age 40 in North America. While both topical and oral medications are available for treating onychomycosis, orals are usually more effective but must be taken for several weeks or months. Existing oral treatments, despite the risk of significant and serious side effects such as liver, kidney and other organ toxicities have a high recurrence rate of the infection (greater than 50%). Current worldwide sales of oral drugs for onychomycosis exceed $1.4 billion and continue to increase in line with aging populations who are more vulnerable to onychomycosis.
Existing topical medications often cannot penetrate the nail well enough to have a therapeutic impact as the fungus infects the full thickness of the nail and the tissue under the nail.

Superficial Pain (NRI-ANA)

Nuvo is also developing topical pain medication for superficial pain conditions such as neuropathic pain and soft tissue injuries. NRI-ANA is being designed to provide fast, effective pain relief in a pleasing, emollient formulation.

Acute Pain (NRI-1005)

A further extension of Nuvo’s topical NSAID pipeline, NRI-1005 is a topical gel formulation designed for the relief of Acute Pain conditions such as sprains, strains and other soft-tissue injuries.

NRI-1002, NRI-1005 and NRI-ANA are being developed with fqubed, Inc. ("fqubed") screening technology. For more information on fqubed’s screening technologies for transdermal drug delivery, please visit our technology section.